Melanoma — Vaccine Treatment in Combination With IL-2 and Treated Lymphocytes for Advanced Melanoma
Citation(s)
Phase II Study in Metastatic Melanoma Using Lymphocytes Reactive With the gp100 Antigen and Immunization Using a Recombinant rF-gp100P209 Virus Encoding a gp100 Peptide Following a Nonmyeloablative Lymphocyte Depleting Regimen